Analysts have clear opinions on VCYT.

There are 2 analysts on the Wall offering 12 month price targets for Veracyte in the last 3 months. The average price target is $34.50 with a high forecast of $35.00 and a low forecast of $34.00. The average price target represents a 31.88% increase from the last price of $26.16.
Veracyte, Inc. (VCYT) is followed by 2 analysts on the street.

Stephen Unger from Needham rates it a Buy with a target of $34.00.

Similarly, 2 months ago Thomas Flaten of Lake Street Reiterated a Buy with a target of $35.00.

The consensus on the street is null.

What does Veracyte, Inc.(VCYT) do ?
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Veracyte, Inc. (VCYT) Insider Trades

Looking for stocks just like VCYT?

Based on Wall Street analyst research, several stocks are similar to VCYT
They are:
– OCX [Info can be found here: https://www.nasdaq.com/market-activity/stocks/OCX ]
– DGX [Info can be found here: https://www.nasdaq.com/market-activity/stocks/DGX ]
– EXAS [Info can be found here: https://www.nasdaq.com/market-activity/stocks/EXAS ]